This study sought to investigate the need for thrombophilia screening in pediatric migraineurs. The cohort included 45/824 children (5.5%) aged 3-18 years with migraine who were tested for thrombophilia at a tertiary pediatric headache clinic. Results were analyzed by background factors and indications for screening. Rates of thrombotic factors were compared with a healthy historical control group. At least 1 thrombotic factor was positive in 19/45 patients (42%). The total thrombophilia risk rate was higher in patients with aura (n = 32). Lipoprotein(a) was the factor most often abnormal in the thrombophilia group of all factors tested (8/19, 42%), regardless of migraine type or gender. It was the only factor with a significantly higher prevalence in the migraine than the historical control group. Full thrombophilia testing in migraine in pediatric headache clinics does not seem to be justified. The high prevalence of elevated lipoprotein(a) in children with migraine warrants further investigation.
TzourioCTehindrazanariveloAIglésiasS. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995;310(6983):830–833.
2.
CaroleiAMariniCDe MatteisG. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet. 1996;347(9014):1503–1506.
3.
MerikangasKRFentonBTChengSH. Association between migraine and stroke in a large scale epidemiological study of the United States. Arch Neurol. 1997;54(4):362–368.
4.
KurthTWinterACEliassenAH. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610.
5.
ChampalouxSWTepperNKMonsourM. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017:216(5):489.e1-489.e7.
6.
SpectorJTKahnSRJonesMR. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123(7):612–624.
7.
Martínez-SánchezPMartínez-MartínezMFuentesB. Migraine and hypercoagulable states in ischemic stroke. Cephalalgia. 2011;31(16):1609–1617.
8.
CrassardIConardJBousserMG. Migraine and haemostasis. Cephalalgia. 2001;21(6):630–636.
9.
Maitrot-ManteletLHorellouMHMassiouH. Should women suffering from migraine with aura be screened for biological thrombophilia? Results from a cross-sectional French study.Thromb Res. 2014;133(5):714–718.
10.
FerroniPBarbantiPAuriliaC. Procoagulant imbalance in premenopausal women with chronic migraine. Neurology. 2017;89(14):1525–1527.
11.
KovácsKHermánFFilepJ. Platelet aggregation of migraineurs during and between attacks. Cephalalgia. 1990;10(4):161–165.
12.
KalendovskyZAustinJH. “Complicated migraine”: its association with increased platelet aggregability and abnormal plasma coagulations factors. Headache. 1975;15(1):18–35.
13.
Hering-HanitRFriedmanZSchlesingerIEllisM. Evidence for activation of the coagulation system in migraine with aura. Cephalalgia. 2001;21(2):137–139.
14.
TietjenGECollinsSA. Hypercoagulability and migraine. Headache. 2018;58(1):173–183.
15.
KitanoAShimomuraTTakeshimaTTakahashiK. Increased 11-dehydrothromboxane B2 in migraine: platelet hyperfunction in patients with migraine during headache-free period. Headache. 1994;34(9):515–518.
16.
SaccoSMerki-FeldGSÆgidiusKL; European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18(1):108.
17.
KutaiMRavivRLevinC. Migraine and hypercoagulability, are they related? A clinical study of thrombophilia in children with migraine. Br J Haematol. 2011;152(3):349–351.
18.
PilarskaELemkaMBakowskaA. Prothrombotic risk factors in ischemic stroke and migraine in children. Acta Neurol Scand. 2006;114(1):13–16.
19.
LippiGMattiuzziCCervellinG. Meta-analysis of factor V Leiden and prothrombin G20210A polymorphism in migraine. Blood Coagul Fibrinolysis. 2015;26(1):7–12.
20.
FerraraMCapozziLBertoccoF. Thrombophilic gene mutations in children with migraine. Hematology. 2012;17(2):115–117.
21.
BottiniFCelleMECalevoMG. Metabolic and genetic risk factors for migraine in children. Cephalalgia. 2006;26(6):731–737.
22.
BassiBParodiEMessinaM. Screening for genetic and acquired thrombophilia in a cohort of young migrainous patients. J Headache Pain. 2003;4(3):138–145.
23.
VerrottiACieriFPellicciaP. Lack of association between antiphospholipid antibodies and migraine in children. Int J Clin Lab Res. 2000;30:109–111.
24.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
25.
CalhoonMJRossCNPounderE. High prevalence of thrombophilic traits in children with family history of thromboembolism. J Pediatr. 2010;157(3):485–489.
26.
DixonWJ. BMPD Statistical Software. Los Angeles: University of California Press; 1993.
De LaetCWautrechtJCBrasseurD. Plasma homocysteine concentration in a Belgian school-age population. Am J Clin Nutr. 1999;69(5):968–972.
29.
VurkunMVuralÖDemirM. The prevalence of activated protein C resistance and F V Leiden in healthy population of Edirne, Turkey. Turk J Haematol. 2002;19(2):287–291.
30.
GoldenbergNABernardTJHillhouseJ. Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica. 2013;98(5):802–807.
31.
TeofiliLFoàRGionaFLaroccaLM. Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?Haematologica. 2008;93(2):169–172.
32.
RubinoEFerreroMRaineroI. Association of the C677 T polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia. 2009;29(8):818–815.
33.
StuartSCoxHCLeaRAGriffithsLR. The role of the MTHFR gene in migraine. Headache. 2012;52(3):515–520.
34.
NordestgaardBGChapmanMJRayK; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.
35.
PalabricaTMLiuACAronovitzMJ. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med. 1995;1(3):256–259.
36.
MattiuzziCCervellinGLippiG. Epidemiological association between migraine and lipoprotein(a): a systematic review. J Thromb Thrombolysis. 2015;39(1):113–117.
37.
CinziaFDanielaPElenaS. Lipoprotein(a) [Lp(a)]: a possible link between migraine and stroke. Transl Res. 2009;153(1):44–47.
38.
TeberSBektasÖYılmazA. Lipoprotein a levels in pediatric migraine. Pediatr Neurol. 2011;45(4):225–228.
39.
KruitMCvan BuchemMALaunerLJ. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010;30(2):129–136.
40.
AytaçBCoşkunÖAlioğluB. Decreased antioxidant status in migraine patients with brain white matter hyperintensities. Neurol Sci. 2014;35(12):1925–1929.
41.
MarS1KellyJEIsbellS. Prevalence of white matter lesions and stroke in children with migraine. Neurology. 2013;81(16):1387–1389.
